Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review
Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in t...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2014-03, Vol.32 (15), p.1645-1653 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1653 |
|---|---|
| container_issue | 15 |
| container_start_page | 1645 |
| container_title | Vaccine |
| container_volume | 32 |
| creator | Kawai, Kosuke Preaud, Emmanuelle Baron-Papillon, Florence Largeron, Nathalie Acosta, Camilo J |
| description | Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in this review show that vaccination against HZ is likely to be cost-effective. |
| doi_str_mv | 10.1016/j.vaccine.2014.01.058 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1519840869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X14001108</els_id><sourcerecordid>1519840869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-90b74a2aefd979d9b2f85753ed75729ff7f68ca31ffcaf815278ab8579900adb3</originalsourceid><addsrcrecordid>eNqFkk-LFDEQxRtR3HH1IygBEbx0W0knncSDIoP_YMGDCt5COl1ZM_akZ5OekfXTm3ZGF_biKaH41aPqvaqqxxQaCrR7sWkO1rkQsWFAeQO0AaHuVCuqZFszQdXdagWs4zWn8O2sepDzBgBES_X96oxx0XLZylWF6ynPNXqPbg4HjJgzmTw5ats5TJHYSxtinsl3TDvM5FdpwERsHMiufP9U5-BIxH2y42WwL4klLoVSsyNJeAj482F1z9sx46PTe159fff2y_pDffHp_cf1m4vaiU7PtYZecsss-kFLPeieeSWkaHGQQjLtvfSdcral3jvrFRVMKtsXRGsAO_TtefX8qLtL09Ue82y2ITscRxtx2mdDBdWKg-p0QZ_eQjfTPsUyXaGgA9lxCYUSR8qlKeeE3uxS2Np0bSiYJQezMacczJKDAWpKDqXvyUl9329x-Nf11_gCPDsBNheffLLRhXzDqZYryVjhXh85LLYVK5PJLmB0OIRUIjPDFP47yqtbCm4McQnnB15jvtnaZGbAfF6OZrkZygEoBdX-BgajvsQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506076470</pqid></control><display><type>article</type><title>Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Kawai, Kosuke ; Preaud, Emmanuelle ; Baron-Papillon, Florence ; Largeron, Nathalie ; Acosta, Camilo J</creator><creatorcontrib>Kawai, Kosuke ; Preaud, Emmanuelle ; Baron-Papillon, Florence ; Largeron, Nathalie ; Acosta, Camilo J</creatorcontrib><description>Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in this review show that vaccination against HZ is likely to be cost-effective.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.01.058</identifier><identifier>PMID: 24534737</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Allergy and Immunology ; Applied microbiology ; Biological and medical sciences ; Cost-Benefit Analysis ; Cost-effectiveness ; Discount rates ; Economic impact ; Europe ; Fundamental and applied biological sciences. Psychology ; herpes zoster ; Herpes Zoster - prevention & control ; Herpes Zoster Vaccine - economics ; Herpes Zoster Vaccine - therapeutic use ; Human viral diseases ; Humans ; Immunization ; Infectious diseases ; Medical sciences ; Microbiology ; Middle Aged ; Neuralgia, Postherpetic - prevention & control ; North America ; postherpetic neuralgia ; Quality of life ; Quality-Adjusted Life Years ; Sensitivity analysis ; shingles ; Studies ; vaccination ; Vaccination - economics ; vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><ispartof>Vaccine, 2014-03, Vol.32 (15), p.1645-1653</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 26, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-90b74a2aefd979d9b2f85753ed75729ff7f68ca31ffcaf815278ab8579900adb3</citedby><cites>FETCH-LOGICAL-c569t-90b74a2aefd979d9b2f85753ed75729ff7f68ca31ffcaf815278ab8579900adb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1506076470?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28348722$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24534737$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kawai, Kosuke</creatorcontrib><creatorcontrib>Preaud, Emmanuelle</creatorcontrib><creatorcontrib>Baron-Papillon, Florence</creatorcontrib><creatorcontrib>Largeron, Nathalie</creatorcontrib><creatorcontrib>Acosta, Camilo J</creatorcontrib><title>Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in this review show that vaccination against HZ is likely to be cost-effective.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Cost-Benefit Analysis</subject><subject>Cost-effectiveness</subject><subject>Discount rates</subject><subject>Economic impact</subject><subject>Europe</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>herpes zoster</subject><subject>Herpes Zoster - prevention & control</subject><subject>Herpes Zoster Vaccine - economics</subject><subject>Herpes Zoster Vaccine - therapeutic use</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Neuralgia, Postherpetic - prevention & control</subject><subject>North America</subject><subject>postherpetic neuralgia</subject><subject>Quality of life</subject><subject>Quality-Adjusted Life Years</subject><subject>Sensitivity analysis</subject><subject>shingles</subject><subject>Studies</subject><subject>vaccination</subject><subject>Vaccination - economics</subject><subject>vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk-LFDEQxRtR3HH1IygBEbx0W0knncSDIoP_YMGDCt5COl1ZM_akZ5OekfXTm3ZGF_biKaH41aPqvaqqxxQaCrR7sWkO1rkQsWFAeQO0AaHuVCuqZFszQdXdagWs4zWn8O2sepDzBgBES_X96oxx0XLZylWF6ynPNXqPbg4HjJgzmTw5ats5TJHYSxtinsl3TDvM5FdpwERsHMiufP9U5-BIxH2y42WwL4klLoVSsyNJeAj482F1z9sx46PTe159fff2y_pDffHp_cf1m4vaiU7PtYZecsss-kFLPeieeSWkaHGQQjLtvfSdcral3jvrFRVMKtsXRGsAO_TtefX8qLtL09Ue82y2ITscRxtx2mdDBdWKg-p0QZ_eQjfTPsUyXaGgA9lxCYUSR8qlKeeE3uxS2Np0bSiYJQezMacczJKDAWpKDqXvyUl9329x-Nf11_gCPDsBNheffLLRhXzDqZYryVjhXh85LLYVK5PJLmB0OIRUIjPDFP47yqtbCm4McQnnB15jvtnaZGbAfF6OZrkZygEoBdX-BgajvsQ</recordid><startdate>20140326</startdate><enddate>20140326</enddate><creator>Kawai, Kosuke</creator><creator>Preaud, Emmanuelle</creator><creator>Baron-Papillon, Florence</creator><creator>Largeron, Nathalie</creator><creator>Acosta, Camilo J</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140326</creationdate><title>Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review</title><author>Kawai, Kosuke ; Preaud, Emmanuelle ; Baron-Papillon, Florence ; Largeron, Nathalie ; Acosta, Camilo J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-90b74a2aefd979d9b2f85753ed75729ff7f68ca31ffcaf815278ab8579900adb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Cost-Benefit Analysis</topic><topic>Cost-effectiveness</topic><topic>Discount rates</topic><topic>Economic impact</topic><topic>Europe</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>herpes zoster</topic><topic>Herpes Zoster - prevention & control</topic><topic>Herpes Zoster Vaccine - economics</topic><topic>Herpes Zoster Vaccine - therapeutic use</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Neuralgia, Postherpetic - prevention & control</topic><topic>North America</topic><topic>postherpetic neuralgia</topic><topic>Quality of life</topic><topic>Quality-Adjusted Life Years</topic><topic>Sensitivity analysis</topic><topic>shingles</topic><topic>Studies</topic><topic>vaccination</topic><topic>Vaccination - economics</topic><topic>vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kawai, Kosuke</creatorcontrib><creatorcontrib>Preaud, Emmanuelle</creatorcontrib><creatorcontrib>Baron-Papillon, Florence</creatorcontrib><creatorcontrib>Largeron, Nathalie</creatorcontrib><creatorcontrib>Acosta, Camilo J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kawai, Kosuke</au><au>Preaud, Emmanuelle</au><au>Baron-Papillon, Florence</au><au>Largeron, Nathalie</au><au>Acosta, Camilo J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2014-03-26</date><risdate>2014</risdate><volume>32</volume><issue>15</issue><spage>1645</spage><epage>1653</epage><pages>1645-1653</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Highlights • We reviewed 15 cost-effectiveness studies of vaccination against herpes zoster (HZ) in North America and Europe. • Differences in results are likely due to varying assumptions about duration of vaccine protection and quality-adjusted life years (QALY) loss due to HZ. • Most studies in this review show that vaccination against HZ is likely to be cost-effective.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>24534737</pmid><doi>10.1016/j.vaccine.2014.01.058</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2014-03, Vol.32 (15), p.1645-1653 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1519840869 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Aged Aged, 80 and over Allergy and Immunology Applied microbiology Biological and medical sciences Cost-Benefit Analysis Cost-effectiveness Discount rates Economic impact Europe Fundamental and applied biological sciences. Psychology herpes zoster Herpes Zoster - prevention & control Herpes Zoster Vaccine - economics Herpes Zoster Vaccine - therapeutic use Human viral diseases Humans Immunization Infectious diseases Medical sciences Microbiology Middle Aged Neuralgia, Postherpetic - prevention & control North America postherpetic neuralgia Quality of life Quality-Adjusted Life Years Sensitivity analysis shingles Studies vaccination Vaccination - economics vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye |
| title | Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T20%3A43%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20vaccination%20against%20herpes%20zoster%20and%20postherpetic%20neuralgia:%20a%20critical%20review&rft.jtitle=Vaccine&rft.au=Kawai,%20Kosuke&rft.date=2014-03-26&rft.volume=32&rft.issue=15&rft.spage=1645&rft.epage=1653&rft.pages=1645-1653&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2014.01.058&rft_dat=%3Cproquest_cross%3E1519840869%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1506076470&rft_id=info:pmid/24534737&rft_els_id=1_s2_0_S0264410X14001108&rfr_iscdi=true |